Bluestein R H & Co. maintained its position in Fresenius Medical Care Corporation (NYSE:FMS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the company’s stock at the close of the second quarter. Bluestein R H & Co.’s holdings in Fresenius Medical Care Corporation were worth $483,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Level Four Advisory Services LLC lifted its holdings in shares of Fresenius Medical Care Corporation by 0.5% in the first quarter. Level Four Advisory Services LLC now owns 11,434 shares of the company’s stock worth $478,000 after acquiring an additional 58 shares during the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Fresenius Medical Care Corporation by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after acquiring an additional 81 shares during the last quarter. Greenleaf Trust lifted its holdings in shares of Fresenius Medical Care Corporation by 2.6% in the second quarter. Greenleaf Trust now owns 4,992 shares of the company’s stock worth $241,000 after acquiring an additional 126 shares during the last quarter. Sawtooth Solutions LLC lifted its holdings in shares of Fresenius Medical Care Corporation by 2.9% in the second quarter. Sawtooth Solutions LLC now owns 4,887 shares of the company’s stock worth $236,000 after acquiring an additional 137 shares during the last quarter. Finally, Wrapmanager Inc. lifted its holdings in shares of Fresenius Medical Care Corporation by 2.4% in the second quarter. Wrapmanager Inc. now owns 7,392 shares of the company’s stock worth $357,000 after acquiring an additional 170 shares during the last quarter. 2.61% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/24/fresenius-medical-care-corporation-fms-position-maintained-by-bluestein-r-h-co.html.

Fresenius Medical Care Corporation (FMS) opened at 48.11 on Friday. The company has a 50-day moving average of $47.05 and a 200-day moving average of $46.00. The company has a market cap of $29.53 billion, a price-to-earnings ratio of 20.65 and a beta of 0.48. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.05). The firm had revenue of $4.47 billion during the quarter, compared to analysts’ expectations of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.96 EPS. Equities research analysts expect that Fresenius Medical Care Corporation will post $2.34 EPS for the current fiscal year.

A number of research analysts have recently commented on FMS shares. DZ Bank AG reissued a “neutral” rating on shares of Fresenius Medical Care Corporation in a report on Monday, May 29th. Royal Bank Of Canada reissued a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care Corporation in a report on Tuesday, May 30th. Nord/LB reissued a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. UBS AG reissued a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Finally, Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $48.67.

Fresenius Medical Care Corporation Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care Corporation (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.